Nov 08, 2022 / 04:25PM GMT
Rich Law - Credit Suisse Group - Analyst
Hey, let's get going. Good afternoon. My name is Rich Law. I'm a senior biotech analyst at CS. I'd like to welcome our next session with Nurix and joining us will be Arthur Sands, President and CEO; and Hans van Houte, CFO. And I think we're going to kick it off with a presentation from you guys. And we'll kick it off on that.
Arthur Sands - Nurix Therapeutics, Inc. - President, CEO, and Board Director
That is correct. Thank you very much, Rich. Let me just stand up so I can look at the big screen too. We will be making certain forward-looking statements so I refer you to our filings with the SEC regarding the risk factors that face our business.
So Nurix, we're a small molecule drug discovery company, we're not oncology. We have four programs in clinical development.
At the center of our drug discovery system at Nurix is the E3 ligase which is pictured here in the center of the screen. It's an enzyme complex system. There are over 600 E3 ligases encoded in the human genome, and these control all
Nurix Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers